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See Article, pages 636–646More than 30 years ago controlled clinical trials demonstrated that
treatment with steroids improves the outcome of patients with
autoimmune hepatitis (AIH) decisively. Azathioprine was soon
found to add beneﬁt in the therapy of AIH and was shown to be
the drug of choice for maintenance therapy. Since then, corticoste-
roid monotherapy and the combination of steroids with azathio-
prine have become the standard of treatment for AIH [1,2]. The
excellent response rates and the fact thatAIH is a raredisease requir-
ingmulticenter efforts on theonehandand limitedcommercial ben-
eﬁt on the other hand have led to a lack of larger controlled clinical
trials evaluating alternative ﬁrst line treatment options thereafter.
Using high dose prednisolone initially (0.5–1 mg/kg/d) in
combination with azathioprine at a dose of 1–1.5 mg/kg/d in
patients not severely jaundiced leads to complete and partial bio-
chemical response rates in over 90% of patients within the ﬁrst
year of treatment and to an excellent long term survival [3,4].
This regimen is frequently used in European countries. One could,
therefore, argue that there is no need for alternative ﬁrst line
treatments of AIH. However, up to 10% of patients do not respond
sufﬁciently to the combination of prednisolone and azathioprine
and another 5–10% experience side effects requiring treatment
modiﬁcation [1,5]. Side effects include the more frequent gastro-
intestinal complaints induced by azathioprine but also serious
toxicity such as pancreatitis, cholestatic hepatitis, and neutrope-
nia. Steroid related side effects include the multiple short term
effects of high dose steroid therapy such as weight gain, diabetes,
and psychosis and the long term effects on bone, eyes, and skin
among others [1]. Budesonide has recently been demonstrated
as a potential alternative for prednisolone with possibly less ste-
roid side-effects in the so far largest controlled clinical trial of AIH
[6], but the clinical value of budesonide remains controversial [2].
In this context, the study by Zachou et al. reported in this issue
of the Journal [7] evaluated mycophenolate mofetil (MMF) in
combination with prednisolone as an alternative to azathioprine
in the ﬁrst line treatment of AIH. MMF is a prodrug of mycophen-
olic acid, which is an inhibitor of inosine monophosphate dehy-
drogenase, the rate limiting enzyme in the de novo purine
synthesis which is required for the proliferation of B- and T-lym-Journal of Hepatology 20
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of purine synthesis and, therefore, MMF targets preferentially the
cells involved in the pathogenesis of AIH. MMF has widely
replaced azathioprine in solid organ transplantation, mainly
due to its faster onset of action and potentially greater immuno-
suppressive capacity reducing rejection episodes as seen after
cardiac and renal transplantation, albeit at the cost of a higher
rate of infections [9,10]. In liver transplantation, the superiority
of MMF over azathioprine is less clear [11]. Moreover, the exact
role of MMF as compared to azathioprine in the treatment of
autoimmune diseases and vasculitis syndromes still has to be
deﬁned [12] and a recent controlled treatment trial of ANCA asso-
ciated vasculitis concluded that MMF was inferior to azathioprine
for the maintenance of remission [13].
To date, there have been no controlled clinical trials evaluat-
ing MMF in treatment naïve or treatment experienced patients
with AIH. Although the study presented by Zachou et al. is a case
series and not a controlled trial comparing azathioprine and
MMF, the data were acquired prospectively according to a treat-
ment protocol. Treatment consisted of prednisolone at a median
initial dose of 0.5–1 mg/kg/d in combination with MMF at a med-
ian dose of 1.5–2 g/d. Biochemical response rates were excellent,
with 88% of the 59 patients included achieving a complete bio-
chemical remission within the ﬁrst year of treatment and the
other 12% achieving a partial remission. Seventy percent of those
patients treated for more than one year were off steroids. Of note,
only 3.4% of patients had to discontinue treatment due to MMF
related side effects, which is considerably lower than the num-
bers reported for azathioprine [1] and for the use of MMF as sec-
ond line treatment of AIH [14,15]. However, this may be
confounded by the fact that patients had to take MMF for more
than three months in order to be included into the study.
This study represents the ﬁrst larger series of patients in
whom an alternative to azathioprine as ﬁrst line treatment of
AIH has been investigated prospectively. The authors should be
applauded for that. The strengths of the study are the prospective
design and the large number of patients included from a single
center. Also, the strict criteria applied for the deﬁnition of a bio-
chemical remission, namely normalization of transaminases as
well as immunoglobulins need to be mentioned. Other trials have
used less stringent criteria (e.g. normalization of transaminases
only [6] making a direct comparison of case series and controlled11 vol. 55 j 510–511
JOURNAL OF HEPATOLOGY
trials of AIH difﬁcult. This is important because achieving a
biochemical remission inﬂuences long term outcome and the
combination of normal transaminases and normal IgG/gamma-
globulins may best predict the lack of histological activity
[3,16,17]. Obviously, the major weakness of the study is the lack
of a direct or historical comparison with azathioprine from the
same center. From the data presented, MMF seems to compare
favorably with other reports using azathioprine with regard to
its efﬁcacy and seems to have considerably less side effects, but
this may be a too optimistic interpretation of the data.
So, should we use MMF as ﬁrst line treatment of patients with
AIH? In the direct comparison of the two drugs, MMF has several
disadvantages. The ﬁrst major disadvantage concerns treatment
costs. Sincemaintenance treatmentmay be life long for themajor-
ity of patients with AIH, treatment costs have clearly to be taken
into consideration [18]. The costs of MMF would be around 15
times higher than those of azathioprine. Since azathioprine is an
efﬁcient drug for most patients with AIH, these incremental costs
would be hard to justify. The second disadvantage is that MMF
has been associated with ﬁrst trimester pregnancy loss and fetal
malformations and is, therefore, contraindicated in pregnancy.
Azathioprine on the other hand seems to be rather safe, although
prematurity may be an issue [19]. This is relevant since many
female patients with ﬁrst presentation of AIHwill be in child bear-
ing age. Thirdly, long term side effects ofMMF in patientswith AIH
are not known. Whether these disadvantages would be out-
weighed by the efﬁcacy and side effect proﬁle of MMF cannot be
answered from the data available. Clearly it would be desirable
to answer this question in a controlled clinical trial. However, the
chances for such a trial to be performed are low.
If not using MMF ﬁrst line, is there a role for MMF in the sec-
ond line treatment of patients with AIH? There are several small
case series describing the usefulness of MMF in patients intoler-
ant to azathioprine or with insufﬁcient response to the drug [14–
16]. Response rates in this setting may be as high as 30–80% but
are difﬁcult to interpret since the patient populations are heter-
ogenous as is the deﬁnition of response. Two studies may give
us clues as to the target population best suited for second line
MMF treatment. In the study by Hennes et al., 12/27 patients
intolerant to azathioprine entered remission under MMF in con-
trast to only 2/9 patients with prior insufﬁcient response to aza-
thioprine [15]. In the recent study of Sharzehi et al., none of the
12 patients with azathioprine non-response entered remission
under MMF whereas 8/9 patients with prior azathioprine intoler-
ance maintained remission under MMF [20]. This indicates that,
in patients with prior insufﬁcient response to azathioprine, more
potent immunosuppressive drugs preferably with an alternative
mode of action, such as cyclosporine A, tacrolimus, cyclophos-
phamide, or inﬂiximab may be used [1,2].
In rare and heterogeneous clinical conditions such as AIH,
medical progress is often made by a thoughtful combination of
case series, clinical experience, and some clinical trials. This pro-
cess has helped many of our patients. The present case series in
conjunction with the other case series to MMF in AIH are the
basis for a sensible clinical recommendation: MMF appears safe
and effective in AIH, but there is no reason to make it the
ﬁrst-line drug in patients who could be managed by relatively
low doses of azathioprine. However, in patients with limiting
side-effects on azathioprine, MMF should be tried. The best
alternative in patients, whose disease is not sufﬁcientlyJournal of Hepatology 201controlled with azathioprine and steroids, remains open to
future studies.
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